Senior Editor / Promotions Producer
Christopher McPherson is a Senior Editor and Promotions Producer for Collider. With a focus on entertainment news and pop culture, Christopher covers a wide range of topics including film, television, and celebrity interviews. He brings a passion for storytelling and a deep knowledge of the industry to his articles, providing readers with engaging and informative content.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
DC also announced an animated Justice League film coming soon.
By: Christopher Mcpherson
Nathalie Emmanuel has also joined Rosario Dawson and Tony Revolori in the genre-bending animated series.
By: Christopher Mcpherson
The film was originally titled 'True Love.'
Driver is starring as Enzo Ferrari, the man behind the car.
By: Christopher Mcpherson
Cranston was speaking at a rally in New York.
By: Christopher Mcpherson
The movie will pass $200 million tomorrow.
By: Christopher Mcpherson
Rebecca Ferguson, Common, and Tim Robbins star in Apple TV+'s most-watched drama.
By: Christopher Mcpherson
The heroes in a half shell arrive in one week.
By: Christopher Mcpherson
Regan MacNeil was on set.
By: Pascal Chanez, Tonya Winders, Adel Mansur, Janwillem Kocks, Christopher Mcpherson, John Haughney, Steve Holmes, Giorgio Walter Canonica, Andrew Menzies-Gow
Asthma affects 339 million people worldwide, with an estimated 5-10% experiencing severe asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and long-term treatment can produce clinically important adverse outcomes and increase the risk of mortality. Therefore, global guidelines recommend limiting the use of OCS. Despite the risks, research indicates that 40-60% of people with severe asthma are receiving or have received long-term OCS treatment. Although often perceived as a low-cost option, long-term OCS use can result in significant health impairments and costs owing to adverse outcomes and increased utilization of healthcare resources. Alternative treatment methods, such as biologics, may produce cost-saving benefits with a better safety profile. A comprehensive and concerted effort is necessary to tackle the continued reliance on OCS. Accordingly, a threshold for OCS use should be established to help identify patients at risk of OCS-related adverse outcomes. Receiving a total dose of more than 500 mg per year should trigger a review and specialist referral. Changes to national and local policies, following examples from other chronic diseases, will be crucial to achieving this goal. Globally, multiple barriers to change still exist, but specific steps have been identified to help clinicians reduce reliance on OCS. Implementing these changes will result in positive health outcomes for patients and social and economic benefits for societies.
(833) 317-6278 
